Sažetak
Uvod/Cilj. Fenomen tumorskog pupljenja sve više biva prepoznat kao značajna determinanta progresije i loše prognoze različitih tipova karcinoma. Cilj studije je bila kliničko-patološka evaluacija ovog fenomena u adenokarcinomu pluća. Metode. Studija je obuhvatila 114 bolesnika operisanih od adenokarcinoma pluća u periodu od jedne godine. Prisustvo i gustina tumorskih pupoljaka analizirani su mikroskopski. Dobijeni rezultati su upoređivani u odnosu na pol i starost bolesnika, veličinu primarnog tumora, nodalni status i stadijum bolesti. Rezultati. U grupi bolesnika sa potvrđenim prisustvom tumorskog pupljenja bilo je 34 (55,7%) muškaraca i 27 (44,3%) žena, a u grupi bez prisustva tumorskog pupljenja 30 (56,6%) muškaraca i 23 (43,4%) žena. Nije uočena statistički značajna razlika u starosnoj dobi između muškog (64,3 ± 6,59 godina) i ženskog pola (63,1 ± 6,53 godina) kod bolesnika sa prisustvom tumorskih pupoljaka u tumorskom tkivu, kao ni kod muškog (63,3 ± 6,02 godina) i ženskog pola (63,2 ± 6,72 godina) kod bolesnika bez tog prisustva. Primarni tumor bio je značajno veći (p < 0.05) kod bolesnica sa fenomenom tumorskog pupljenja. U grupi bolesnika u čijem je tumorskom tkivu dokazan fenomen pupljenja dominirao je nodalni stadijum N1 (p < 0,05) i stadijum III bolesti (p < 0,05). Zaključak. Sa potvrđenom statističkom značajnošću između višeg nodalnog statusa, stadijuma bolesti i tumorskog pupljenja, pokazano je da ovaj fenomen, iako relativno nov u dijagnostičkom domenu patologije, privlači dodatnu pažnju kao značajan prognostički faktor. Dobijeni rezultati bi mogli pomoći u integrisanju ovog fenomena u postojeće skoring sisteme kao dodatka ostalim prediktorima koji ukazuju na lošiju prognozu bolesti.
Ključne reči
Array
Array
Array
Array
Array
Reference
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5): 277‒300.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64(1): 9‒29.
Kerr KM. Personalized medicine for lung cancer: new challeng-es for pathology. Histopathology 2012; 60(4): 531–46.
Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of pa-tients with lung adenocarcinoma. Nat Med 2002; 8(8): 816–24.
Coate LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009; 10: 1001–10.
Šolajić N. Prognostic significance of density of tumor buds and cytoplasmic pseudofragments in stage II colonic carcinoma [dissertation]. Novi Sad: Faculty of Medicine, University of Novi Sad; 2016. (Serbian)
Kalluri R, Weinberg RA. The basics of epithelialmesenchymal transition. J Clin Invest 2009; 119(6): 1420–8.
Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial-mesenchymal transitions: the importance of chang-ing cell state in development and disease. J Clin Invest 2009; 119(6): 1438‒49.
Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as on-cotarget. Oncotarget 2010; 1(7): 651‒61.
Kalluri R. EMT: when epithelial cells decide to become mes-enchymal- like cells. J Clin Invest 2009; 119(6): 1417‒9.
Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer—ready for diagnostic practice? Human Pathology 2016; 47(1): 4‒19.
Dawson H, Lugli A. Molecular and pathogenetic aspects of tu-mor budding in colorectal cancer. Front Med (Lausanne) 2015; 2: 11.
Masuda R, Kijima H, Imamura N, Aruga N, Nakamura Y, Masu-da D, et al. Tumor budding is a significant indicator of a poor prognosis in lung squamous cell carcinoma patients. Mol Med Rep 2012; 6(5): 937‒43.
Gabbert H, Wagner R, Moll R, Gerharz CD. Tumor dedifferen-tiation: an important step in tumor invasion. Clin Exp Metas-tasis 1985; 3(4): 257–79.
Prall F. Tumour budding in colorectal adenocarcinoma. His-topathology 2007; 50(1): 151‒62.
Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour “budding” as an index to estimate the potential of aggressive-ness in rectal cancer. Histopathology 2002; 40(2): 127‒32.
Sy J, Fung CL, Dent OF, Chapius PH, Bokey L, Chan C. Tumor budding and survival after potentially curative resection of node- positive colon cancer. Dis Colon Rectum 2010; 53(3): 301‒7.
Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Modern Patholo-gy 2012; 25(10): 1315‒25.
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Clas-sification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification. J Thorac Oncol 2015; 10(9): 1243–60.
Eguchi T, Kadota K, Park BJ, Travis WD, Jones DR, Adusumilli PS, et al. The New IASLC/ATS/ERS Lung Adenocarcinoma Classification: what the surgeon should know. Semin Thorac Cardiovasc 2014; 26(3): 210‒22.
Imai T. The growth of human carcinoma: a morphological analysis. Fukuoka Igaku Zasshi 1954; 45: 72‒102.
Grigore AD, Jolly MK, Jia D, Farach-Carson MC, Levine H. Tu-mor Budding: The Name is EMT. Partial EMT. J Clin Med 2016; 5(5): pii: E51.
Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II well-differentiated or mod-erately differentiated colon adenocarcinoma. Dis Colon Rec-tum 2003; 46(10): 1400‒6.
Guzinska-Ustymowicz K. The role of tumour budding at the front of invasion and recurrence of rectal carcinoma. Anti-cancer Res 2005; 25(2B): 1269‒72.
Prall F, Nizze H, Barten M. Tumour budding as prognostic fac-tor in stage I/II colorectal carcinoma. Histopathology 2005; 47(1): 17–24.
Zlobec I, Hädrich M, Dawson H, Koelzer VH, Borner M, Mallaev M, et al. Intratumoural budding (ITB) in preoperative biop-sies predicts the presence of lymph node and distant metasta-ses in colon and rectal cancer patients. Br J Cancer 2014; 110(4): 1008‒13.
Koelzer VH, Zlobec I, Berger MD, Cathomas G, Dawson G, Dirschmid K, et al. Tumor budding in colorectal cancer revisit-ed: Results of a multicenter interobserver study. Virchows Arch 2015; 466(5): 485–93.
Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor “budding” in patients with colorectal cancer. Dis Colon Rectum 1993; 36(7): 627–35.
Nakamura T, Mitomi H, Kikuchi S, Ohtani Y, Sato K. Evaluation of the usefulness of tumor budding on the prediction of me-tastasis to the lung and liver after curative excision of colorec-tal cancer. Hepatogastroenterology 2005; 52(65): 1432‒5.
Wang LM, Kevans D, Mulcahy H, O’Sullivan J, Fennelly D, Hy-land J, et al. Tumor budding is a strong and reproducible prog-nostic marker in T3N0 colorectal cancer. Am J Surg Pathol 2009; 33(1): 134–41.
Kadota K, Yeh Y, Villena-Vargas J, Cherkassky L, Drill EN, Si-ma CS, et al. Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma. Chest 2015; 148(3): 711‒21.
Yu K, Zhang C, Berry GJ, Altman RB, Re C, Rubin DL, et al. Predicting non-small cell lung cancer prognosis by fully auto-mated microscopic pathology image features. Nat Commun 2016; 7: 12474.
Yamaguchi Y, Ishii G, Kojima M, Yoh K, Otsuka H, Otaki Y, et al. Histopathologic Features of the Tumor Budding in Adeno-carcinoma of the Lung. Tumor Budding As an Index to Pre-dict the Potential Aggressiveness. J Thorac Oncol 2010; 5: 1361‒8.
Wang C, Huang H, Huang Z, Wang A, Chen X, Huang L, et al. Tumor budding correlates with poor prognosis and epithelial-mesenchymal transition in tongue squamous cell carcinoma. J Oral Pathol Med 2011; 40(7): 545–51.
O’Connor K, Li-Chang HH, Kalloger SE, Peixoto RD, Webber DL, Owen DA, et al. Tumor budding is an independent ad-verse prognostic factor in pancreatic ductal adenocarcinoma. Am J Surg Pathol 2015; 39(4): 472–8.
Karamitopoulou E, Zlobec I, Born D, Kondi-Pafiti A, Lykoudis P, Mellou A, et al. Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Eur J Cancer 2013; 49(5): 1032‒9.
Salhia B, Trippel M, Pfaltz K, Cihoric N, Grogg A, Lädrach C, et al. High tumor budding stratifies breast cancer with metastatic properties. Breast Cancer Res Treat 2015; 150(2): 363‒71.
Almangush A, Salo T, Hagström J, Leivo I. Tumour budding in head and neck squamous cell carcinoma - a systematic review. Histopathology 2014; 65(5): 587‒94.
Manjula BV, Augustine S, Selvam S, Mohan AM. Prognostic and predictive factors in gingivo buccal complex squamous cell carcinoma: role of tumor budding and pattern of invasion. In-dian J Otolaryngol Head Neck Surg 2015; 67(1): 98–104.